YOU, QIDONGProfessor of Medicinal ChemistryDirector of Jiangsu Key Laboratory of Drug Design and OptimizationSchool of PharmacyPhone: 86-25-83271351Email: youqd@cpu.edu.cnResearch SummaryProfessor YOU’s research interesting is on the drug design and synthesis, the action mechanism of drug molecular and new drug research and development. The recent research focuced on two main fields: 1) natural product and its derivatives, structure-activities relationships, structure modification simplification and optimization; 2) Bioactive compound discovery for targeting on the protein structure and function, such as,  protein-protein interaction, protein degradation and the new drug design for cancer.Education1989       Ph.D., Medicinal Chemistry, Shanghai Institute of Pharmaceutical Industry1985       M.S.,  Medicinal Chemistry, Shanghai Institute of Pharmaceutical Industry1982       B.S.,   Medicinal Chemistry，Nanjing College of Pharmacy (the former of China Pharmaceutical University)Academic Experience1994-      Professor of Medicinal Chemistry, China Pharmaceutical University, Associate Dean of School of Pharmacy (1995 to 2009), Dean of School of Pharmacy (2009 to 2015),1994-1995  Senior Visiting Scholar, University of Strathclyde, UK1990-1994 Associate Professor of Medicinal Chemistry, China Pharmaceutical University,Awards and Honors1994      Henry Fok outstanding young teachers Award, Henry Fok Education Foundation2013       Wu Jieping-Paul Janssen Award in medicine & Pharmacy, Ministry of Health2016       First prize for scientific and technological progress of Jiangsu，Jiangsu Province 2012       Second prize for scientific and technological progress of Jiangsu，Jiangsu Province2007       Second prize for scientific and technological progress of Jiangsu，Jiangsu Province2014       Second prize for National Teaching Achievement Award, Ministry of Education2009       Second prize for National Teaching Achievement Award, Ministry of Education PublicationsBooks (selected):Chiral Drugs: Chemistry and Biological Action. Ed by Guo-Qiang Lin, Qi-Dong You and Jie-Fei Cheng, John Wiley & Sons, Inc. Hoboken, 2011Research and Evaluation of Chiral Drugs, Ed by Qi-Dong You and Guo-Qiang Lin, Chemical Industry Press. Beijing, 2011Medicinal Chemistry, 3rd edition, Ed by Qi-Dong You, Chemical Industry Press. Beijing, 2015Papers and Articles (selected)Palladium(II)-Catalyzed C-H Bond Activation/C-C Coupling/Intramolecular Tsuji-Trost Reaction Cascade: Facile Access to 2H-Pyranonaphthoquinones. Bian, Jinlei; Qian, Xue; Wang, Nan; Mu, Tong; Li, Xiang; Sun, Haopeng; Zhang, Lianshan; You, Qidong; Zhang, Xiaojin. Org Lett. 2015, 17 (14):3410–3413Structure-Activity and Structure-Property Relationship and Exploratory in vivo Evaluation of the Nanomolar Keap1-Nrf2 Protein-Protein Interaction Inhibitor. Zhengyu Jiang, Lili Xu, Mengchen Lu, Zhiyun Chen, Zhenwei Yuan, Xiaoli Xu, Xiaoke Guo,Xiaojin Zhang, Haopeng Sun, Qi-Dong You.J. Med. Chem.,2015, 58 (16):6410–6421Discovery and Modification of in vivo active Nrf2 Activators with 1, 2, 4-oxadiazole Core: Hits Identification and Structure-Activity Relationship Study. Xu, Lili; Zhu, Junfeng; Xu, Xiaoli; Zhu, Jie; Li, Li; Xi, Meiyang; Jiang, Zhengyu; Zhang, Mingye; Liu, Fang; Lu, Mengchen; Bao, Qichao; Zhang, Chao; Wei, Jinlian; Zhang, Xiaojin; You, Qi-Dong; Sun, Haopeng. J Med Chem.2015, 58 (14), pp 5419–5436Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: Introduction of an additional carboxyl group at the C-2 position of quinoline. Feng T, Li D, Wang H, Zhuang J, Liu F, Bao Q, Lei Y, Chen W, Zhang X, Xu X, Sun H, You Q, Guo X.Eur J Med Chem. 2015, 105:145-155.Binding thermodynamics and kinetics guided optimization of potent Keap1-Nrf2 peptide inhibitors. Lu, M.-C.; Chen, Z.-Y.; Wang, Y.-L.; Jiang, Y.-L.; Yuan, Z.-W.; You, Q.-D. *; Jiang, Z.-Y. *RSC Advances 2015, 5:85983-85987Identification of Novel JMJD2A Inhibitor Scaffold Using Shape and Electrostatic Similarity Search Combined with Docking Method and MM-GBSA Approach. Feng, T. T.; Chen, W. L.; Li, D. D.; Lin, H. Z.; Liu, F.; Bao, Q. C.; Lei, Y. H.; Zhang, X. J.; Xu, X. L.; Guo, X. K.; You, Q. D.*; Sun, H. P.*RSC Advances,2015, 5:82936-82946.Discovery of NAD(P)H:quinone oxidoreductase 1 (NQO1) inhibitors with novel chemical scaffolds by shape-based virtual screening combined with cascade docking. Bian, J.; Qian, X.; Deng, B.; Xu, X.; Guo, X.; Wang, Y.;* Li, X.; Sun, H.; You, Q.;* Zhang, X.*RSC Advances, 2015, 5 (61), 49471-49479. Affinity-based fluorescence polarization assay for high-throughput screening of prolyl hydroxylase 2 inhibitors. Lei, Y.; Hu, T.; Wu, X.; Wu, Y.; Bao, Q.; Zhang, L.; Xia, H.; Sun, H.; You, Q.;* Zhang, X.* ACS Med. Chem. Lett., 2015, 6 (12), 1236−1240. (IF=3.120)CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells. Xiao-Li Xu, Qi-chao Bao, Jian-Min Jia, Fang Liu, Xiao-Ke Guo, Ming-ye Zhang, Jin-lian Wei, Meng-chen Lu, Li-li Xu, Xiao-Jin Zhang, Qi-Dong You & Hao-Peng Sun.Scientific Reports2016, 6:19004A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides. Lu, Meng-Chen, ,Yuan, Zhen-Wei,  Jiang, Yong-Lin, Chen, Zhi-Yun, You, Qi-Dong, Jiang, Zheng-Yu.Mol. BioSyst.,2016,12(4):1378-1387

YANG, PENGYANG, PENGProfessor of Medicinal ChemistryEmail: pengyang@cpu.edu.cnResearch SummaryProfessor YANG’s research focuses on identification of new drug targets and novel leading compounds, drug design and chemical synthesis, the action mechanism of drug molecular, and new drug research and development. The recent research focused on three main fields: (1) natural products and small molecules, structure-activity relationship studies, chemical modification and optimization, bioactivity evaluation at cell- and animal-levels; (2) discovery of new drug targets and novel leading compounds through unique virtual screening; (3) interaction studies between small molecule and protein target, mechanism studies at molecule level.Education2008: Ph. D., Medicinal Chemistry, Chinese Academy of Medical Sciences and Peking Union Medical College, Tsinghua University2005: M.S., Medicinal Chemistry, Chinese Academy of Medical Sciences and Peking Union Medical College2002: B.S., Pharmacy, School of Pharmacy, Shandong University  Academic Experience2018.03-present: Professor of Medicinal Chemistry, China Pharmaceutical University2017.08-2018.02: Associate Director of Medicinal Chemistry, Bioduro (Shanghai) Co., Ltd2015.11-2017.07: Assistant Professor, University of Pittsburgh, USA2011.06-2015.10: Post-doctoral Research Associate, University of Pittsburgh, USA2008.08-2011.05: Senior Scientist & Group Leader, Bioduro (Beijing) Co., LtdAwards and Honors2015      Outstanding Research Achievements Award2007      “Professor Satoshi Omura” Award2004      “Academician Zhen Yongsu” AwardPublicationsCha-Molstad H.#, Yu J.#, Feng Z.#, Lee S.#, Kim J.#, Yang P.# (equal contribution), Yoo Y., Hwang J., McGuire T., Shim S., Song H., Ganipisetti S., Wang N., Jang J., Lee M., Kim S., Lee K., Hong J., Ciechanover A., Mook-Jung I., Xie X-Q*, Kwon Y.*, and Kim B.* p62/SQSTM1 Is an Autophagic Inducer Mediating Crosstalk between the Ubiquitin-Proteasome System and Autophagy. Nat Commun. 2017, 8(1):102.Teramachi J.#, Silberma R.#, Yang P.# (equal contribution), Zhao W., Mohammad K., Guo J, Anderson JL, Zhou D, Feng R, Myint KZ, Maertz N, Beumer JH, Eiseman JL, Windle JJ, Xie XQ*, Roodman GD*, Kurihara N*.. Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo. Leukemia, 2016; 30(2):390-8.Gao Y#, Yang P# (equal contribution), Shen H#, Yu H, Song X, Zhang L, Zhang P, Cheng H, Xie Z, , Dong F, Ma S, Ji Q, Bartlow P, Ding Y, Wang L, Liu H, Li Y, Cheng H, Miao W, Yuan W, Yuan Y, Cheng T*, Xie XQ*: Small-molecule inhibitors targeting INK4 protein p18(INK4C) enhance ex vivo expansion of haematopoietic stem cells. Nat Commun. 2015, 6:6328.Yang P., Wang L., Feng R., Almehizia A.A., Tong Q., Myint K.Z., Ouyang Q., Alqarni M.H., Wang L., Xie X.Q.* Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation. J. Med. Chem. 2013, 14; 56 (5):2045-58.Yang, P.#; Myint, K. Z.#; Tong, Q.; Feng, R.; Cao, H.; Almehizia, A. A.; Bartlow, P.; Gertsch, J.; Teramachi, J.; Kurihara, N.; Roodman, G. D.; Cheng, T.; Xie, X. Q.* Lead Discovery, Chemistry Optimization and Biological Evaluation Studies of Novel Bi-amide Derivatives as CB2 Receptor Inverse Agonists and Osteoclast Inhibitors. J. Med. Chem. 2012, 55, 9973-9987.